International Prognostic Scoring System for Waldenstrom Macroglobulinemia

Estimate prognosis with the IPPSWM

About

The IPSSWM was derived after merging a cohort of patients with WM from 7 international co-operative groups. The IPSSWM speicifcially focuse on symptomatic patinets requiring therapy, and the majority were treated with standard therapies including alkylating agents, purine analogs, and rituximab.

References

Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G.

Blood. 2009 Apr 30;113(18):4163-70. doi: 10.1182/blood-2008-08-174961. Epub 2009 Feb 5.
Default Units

1. Age

0/5 completed

About

The IPSSWM was derived after merging a cohort of patients with WM from 7 international co-operative groups. The IPSSWM speicifcially focuse on symptomatic patinets requiring therapy, and the majority were treated with standard therapies including alkylating agents, purine analogs, and rituximab.

References

Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G.

Blood. 2009 Apr 30;113(18):4163-70. doi: 10.1182/blood-2008-08-174961. Epub 2009 Feb 5.
Contributed By:
  • Matthew Cheung, MD, FRCP(C)
Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.